Targeting the E3 ubiquitin casitas B‐lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis

Targeting receptor tyrosine kinase (RTK) degradation may be an interesting approach to reduce RTK cell signaling in cancer cells. Here we show that increasing E3 ubiquitin ligase casitas B‐lineage lymphoma (c‐Cbl) expression using lentiviral infection decreased osteosarcoma cell replication and survival and reduced cell migration and invasion in murine and human osteosarcoma cells. Conversely, c‐Cbl inhibition using short hairpin RNA (shRNA) increased osteosarcoma cell growth and survival, as well as invasion and migration, indicating that c‐Cbl plays a critical role as a bone tumor suppressor. Importantly, the anticancer effect of increasing c‐Cbl expression in osteosarcoma cells was related mainly to the downregulation of epidermal growth factor receptor (EGFR) and platelet‐derived growth factor receptor alpha (PDGFRα). In a murine bone tumor model, increasing c‐Cbl expression also reduced RTK expression, resulting in decreased tumor cell proliferation and survival and reduced tumor growth. Interestingly, increasing c‐Cbl also markedly reduced lung metastasis in mice. Tissue microarray analysis revealed that low c‐Cbl protein expression is associated with elevated EGFR and PDGFRα protein levels in human osteosarcoma with poor outcome. This study shows that increasing c‐Cbl expression reduces osteosarcoma cell growth, survival, and metastasis in part through downregulation of RTKs, which supports the potential therapeutic interest of targeting c‐Cbl in malignant bone diseases involving increased RTK. © 2012 American Society for Bone and Mineral Research.

[1]  A. Weissman,et al.  RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis , 2011, Nature Reviews Cancer.

[2]  P. Marie,et al.  The Casitas B Lineage Lymphoma (Cbl) Mutant G306E Enhances Osteogenic Differentiation in Human Mesenchymal Stromal Cells in Part by Decreased Cbl-mediated Platelet-derived Growth Factor Receptor α and Fibroblast Growth Factor Receptor 2 Ubiquitination* , 2011, The Journal of Biological Chemistry.

[3]  Peter F. M. Choong,et al.  The Molecular Pathogenesis of Osteosarcoma: A Review , 2011, Sarcoma.

[4]  James Lowe,et al.  Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets , 2010, Nature Reviews Drug Discovery.

[5]  M. Nau,et al.  Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. , 2010, Cancer Research.

[6]  J. Ringe,et al.  Increased EFG- and PDGFalpha-receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosis. , 2010, Human Molecular Genetics.

[7]  M. Loh,et al.  Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. , 2009, Blood.

[8]  S. Ogawa,et al.  Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms , 2009, Nature.

[9]  T. Hunter Tyrosine phosphorylation: thirty years and counting. , 2009, Current opinion in cell biology.

[10]  O. Fromigué,et al.  Blockade of the RhoA-JNK-c-Jun-MMP2 Cascade by Atorvastatin Reduces Osteosarcoma Cell Invasion* , 2008, Journal of Biological Chemistry.

[11]  A. Sanjay,et al.  FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt signaling and osteoblast survival. , 2008, Bone.

[12]  O. Fromigué,et al.  Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma. , 2007, Cancer research.

[13]  C. Dufour,et al.  Down-regulation of ubiquitin ligase Cbl induced by twist haploinsufficiency in Saethre-Chotzen syndrome results in increased PI3K/Akt signaling and osteoblast proliferation. , 2006, The American journal of pathology.

[14]  A. Tsygankov,et al.  The Cbl family proteins: Ring leaders in regulation of cell signaling , 2006, Journal of cellular physiology.

[15]  J. Wade Harper,et al.  Drug discovery in the ubiquitin–proteasome system , 2006, Nature Reviews Drug Discovery.

[16]  N. Ishimaru,et al.  Ubiquitin Ligase Cbl‐b Downregulates Bone Formation Through Suppression of IGF‐I Signaling in Osteoblasts During Denervation , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  P. Auberger,et al.  RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation , 2006, Cell Death and Differentiation.

[18]  M. Nau,et al.  Regulating the regulator: negative regulation of Cbl ubiquitin ligases. , 2006, Trends in biochemical sciences.

[19]  Ivan Dikic,et al.  The Cbl interactome and its functions , 2005, Nature Reviews Molecular Cell Biology.

[20]  I. Rose Ubiquitin at Fox Chase* , 2005, Cell Death and Differentiation.

[21]  A. Ciechanover Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin–proteasome system and onto human diseases and drug targeting* , 2005, Cell Death and Differentiation.

[22]  P. Marie,et al.  Cbl-mediated ubiquitination of α5 integrin subunit mediates fibronectin-dependent osteoblast detachment and apoptosis induced by FGFR2 activation , 2005, Journal of Cell Science.

[23]  J. Lemonnier,et al.  Cbl-mediated Degradation of Lyn and Fyn Induced by Constitutive Fibroblast Growth Factor Receptor-2 Activation Supports Osteoblast Differentiation* , 2004, Journal of Biological Chemistry.

[24]  Morag Park,et al.  Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. , 2003, Cancer cell.

[25]  Ivan Dikic,et al.  Negative receptor signalling. , 2003, Current opinion in cell biology.

[26]  Y. Yarden,et al.  The role of ubiquitylation in signaling by growth factors: implications to cancer. , 2003, Seminars in cancer biology.

[27]  L. Penengo,et al.  Receptor tyrosine kinases as target for anti-cancer therapy. , 2002, Current pharmaceutical design.

[28]  H. Ding,et al.  Induction of apoptosis in cancer: new therapeutic opportunities , 2002, Annals of medicine.

[29]  A. Tsygankov,et al.  Beyond the RING: CBL proteins as multivalent adapters , 2001, Oncogene.

[30]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[31]  P. Meltzer,et al.  Metastasis-associated differences in gene expression in a murine model of osteosarcoma. , 2001, Cancer research.

[32]  W. Langdon,et al.  Cbl: many adaptations to regulate protein tyrosine kinases , 2001, Nature Reviews Molecular Cell Biology.

[33]  J. Schlessinger Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[34]  J. Lemonnier,et al.  N‐ and E‐cadherin mediate early human calvaria osteoblast differentiation promoted by bone morphogenetic protein‐2 , 2000 .

[35]  Y. Yarden,et al.  The RING Finger of c-Cbl Mediates Desensitization of the Epidermal Growth Factor Receptor* , 1999, The Journal of Biological Chemistry.

[36]  Z. Kam,et al.  c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. , 1998, Genes & development.

[37]  B. Himelstein Osteosarcoma and other bone cancers. , 1998, Current opinion in oncology.

[38]  H. Band,et al.  Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity , 1997, Molecular and cellular biology.

[39]  T. O'Brien,et al.  Therapeutic strategies within the ubiquitin proteasome system , 2010, Cell Death and Differentiation.

[40]  A. Ciechanover,et al.  The ubiquitin proteasome system and its involvement in cell death pathways , 2010, Cell Death and Differentiation.

[41]  N. Jaffe Osteosarcoma: review of the past, impact on the future. The American experience. , 2009, Cancer treatment and research.

[42]  L. Helman,et al.  An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential , 2004, Clinical & Experimental Metastasis.